0000000000306506

AUTHOR

Tanja Veselinović

showing 3 related works from this author

Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas

2010

Quetiapine is next to clozapine an antipsychotic agent that exerts hardly any extrapyramidal side-effects at clinical efficacious doses. Some previous receptor occupancy studies reported preferential extrastriatal D2/3 receptor (D2/3R)-binding properties of second-generation antipsychotics and suggested this as possible reason for improved tolerability. This positron emission tomography (PET) investigation was designed to compare the occupancy of dopamine D2/3Rs by quetiapine in striatal and extrastriatal brain regions. Therefore, a cohort of 16 quetiapine-treated psychotic patients underwent an [18F]fallypride (FP) PET scan. Due to the high affinity of FP and its comparatively long half-li…

AdultMaleDibenzothiazepinesPyrrolidinesCaudate nucleusPharmacologyBinding CompetitiveQuetiapine FumarateYoung AdultQuetiapine FumarateDopamine receptor D2HumansMedicinePharmacology (medical)ClozapineVisual CortexPharmacologyTemporal cortexReceptors Dopamine D2business.industryReceptors Dopamine D3Binding potentialMiddle AgedCorpus StriatumTemporal LobePsychiatry and Mental healthFallypridePositron-Emission TomographyBenzamidesSchizophreniaQuetiapineFemalebusinessAntipsychotic Agentsmedicine.drugThe International Journal of Neuropsychopharmacology
researchProduct

Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclo…

2008

To elucidate the Batypicality( of ziprasidone, its striatal and extrastriatal D2/D3-receptor binding was characterized in patients with schizophrenia under steady-state conditions. These data were compared with striatal receptor occupancy values after single-dose ziprasidone ingestion in healthy controls. ( 18 F)fallypride positron emission tomography (PET) recordings were obtained in 15 patients under steady-state ziprasidone treatment at varying time points after the last dose. Binding potentials were calculated for striatal and extrastriatal regions. D2/D3-receptor occupancies were expressed relative to binding potentials in 8 unmedicated patients. In a parallel ( 11 C)raclopride-PET stu…

AdultMalemedicine.medical_specialtyFluorine RadioisotopesPyrrolidinesTime Factorsmedicine.drug_classAtypical antipsychoticPharmacologyBinding CompetitiveBasal GangliaPiperazinesYoung AdultDopamine receptor D3Internal medicinemedicineHaloperidolHumansPharmacology (medical)ZiprasidoneCarbon RadioisotopesTemporal cortexRacloprideDose-Response Relationship DrugChemistryReceptors Dopamine D2Dopamine antagonistReceptors Dopamine D3Psychiatry and Mental healthThiazolesEndocrinologyFallyprideRaclopridePositron-Emission TomographyBenzamidesSchizophreniaDopamine AntagonistsFemaleRadiopharmaceuticalsmedicine.drugAntipsychotic AgentsJournal of clinical psychopharmacology
researchProduct

Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Me…

2019

Background Impaired subjective well-being in schizophrenia patients treated with antipsychotics has often been linked inter alia to the antidopaminergic effects of medication. Thus, it is important to capture the association between striatal dopamine D2 receptor occupancy (D2-RO) and global subjective well-being. We examined this association using data from our multicenter, randomized, double-blind Neuroleptic Strategy Study (NeSSy). Methods An innovative double randomization process was used for allocation of patients to the specific treatment groups. Plasma drug concentrations were measured after 6 and 24 weeks of treatment to obtain the estimated D2-RO (eD2-RO) relative to literature val…

AdultMaleOlanzapinemedicine.medical_specialtymedicine.medical_treatmentAripiprazolePersonal SatisfactionMedication Adherencelaw.invention03 medical and health sciencesSex Factors0302 clinical medicineDouble-Blind MethodRandomized controlled triallawInternal medicinemedicineHaloperidolHumansPharmacology (medical)AntipsychoticReceptors Dopamine D2business.industryMiddle Agedmedicine.disease3. Good health030227 psychiatryFlupentixolFlupenthixolDopamine D2 Receptor AntagonistsPsychiatry and Mental healthOlanzapineSchizophreniaQuality of LifeSchizophreniaHaloperidolQuetiapineFemaleSchizophrenic PsychologyAripiprazolebusiness030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drugJournal of Clinical Psychopharmacology
researchProduct